Video: Latest Treatment for Hep C.

Hydrocortisone and Pramoxine Cream

Generic Name: hydrocortisone acetate, pramoxine hydrochloride
Dosage Form: cream

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Hydrocortisone Acetate 2.5%-Pramoxine HCl 1% Cream Kit

Rx Only

DESCRIPTION:

Hydrocortisone Acetate 2.5%-Pramoxine HCl 1% Cream is a topical preparation containing Hydrocortisone Acetate 2.5% w/w and Pramoxine HCl 1% w/w in a hydrophilic base containing purified water, cetostearyl alcohol, mineral oil, white petrolatum, propylparaben, triethanolamine laurel sulfate, citric acid, sodium citrate, isopropyl palmitate, stearic acid, lanolin alcohol, methyl paraben, potassium sorbate, sorbic acid, PEG-40 stearate and ceresin wax. Topical corticosteroids are anti-inflammatory and anti-puritic agents. The structural formula, the chemical name, molecular formula and molecular weight for active ingredients are presented below.

Slideshow: Hemorrhoids: A Common Ailment with Frequent Questions

Image Credit: U.S. FDA/Drugs.com

CLINICAL PHARMACOLOGY:

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pramoxine hydrochloride is a topical anesthetic agent which provides temporary relief from itching and pain. It acts by stabilizing the neuronal membrane of nerve endings with which it comes into contact.

Pharmacokinetics:

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION.)

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.

Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE:

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS:

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS:

General:

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area and under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See Precautions-Pediatric Use.)

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the patient:

Patients using topical corticosteroids should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes.
  2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
  3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
  4. Patients should report any signs of local adverse reactions especially under occlusive dressings.
  5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Laboratory Tests:

Urinary free cortisol test and ACTH stimulation test may be helpful in evaluating the HPA axis suppression.

Carcinogenesis, Mutagenesis and Impairment of Fertility:

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy

Teratogenic Effects:

Pregnancy Category C:

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts or for prolonged periods of time.

Nursing Mothers:

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities NOT likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use:

Pediatric patients may demonstrate greater susceptibility to topical corticosteroids induced HPA axis suppression and Cushing's syndrome than mature patients because of larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS:

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

OVERDOSAGE:

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS.)

DOSAGE AND ADMINISTRATION:

Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED:

Hydrocortisone Acetate 2.5%-Pramoxine HCl 1% Cream Kit

1 ounce tube (NDC 42192-118-07)

30 x 4 gram tubes (NDC 42192-119-30)

Storage Conditions:

Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [see USP Controlled Room Temperature].

Rx Only

Manufactured for:

Acella Pharmaceuticals, LLC
9005 Westside Parkway
Alpharetta, GA 30009

Rev. 0110

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Hydrocortisone Acetate 2.5% Pramoxine HCl 1% Cream Carton

NDC 42192-119-30

Hydrocortisone Acetate 2.5% -
Pramoxine HCl 1% Cream Kit

Hydrocortisone Acetate 2.5% - Pramoxine HCl 1% Cream Singles

Each gram contains Hydrocortisone Acetate 2.5% and Pramoxine HCl 1% in a hydrophilic base containing purified water, cetostearyl alcohol, mineral oil, white petrolatum, propylparaben, triethanolamine laurel sulfate, citric acid, sodium citrate, isopropyl palmitate, stearic acid, lanolin alcohol, methyl paraben, potassium sorbate, sorbic acid, PEG-40 stearate and ceresin wax.

Usual Dosage:Apply to affected area 3 - 4 times daily or as directed by a physician. See enclosed package insert for full prescribing information.

Pramoxine HCl 1% Wipes

For temporary relief of discomfort and itch in the perianal area and anogenital cleansing.

Contains: Pramoxine HCl 1% w/w. glycerin, purified water, citric acid, sodium citrate, potassium sorbate, penyoxyethanol.

DIrections: When practical, cleanse the affected area with mild soap and warm water and rinse thoroughly. Gently apply wipe to the affected area by patting and then discard.

Do not use to apply cream.

Brookstone
Pharmaceuticals
is now known as
Acella
Pharmaceuticals, LLC

Hydrocortisone Acetate 2.5% Pramoxine HCl 1% Cream Carton

HYDROCORTISONE ACETATE PRAMOXINE HCL 
hydrocortisone acetate pramoxine hcl kit
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:42192-119
Packaging
# Item Code Package Description
1 NDC:42192-119-30 1 KIT (KIT) in 1 CARTON
Quantity of Parts
Part # Package Quantity Total Product Quantity
Part 1 30 TUBE, WITH APPLICATOR 120 g
Part 2 18 POUCH 108 g
Part 1 of 2
HYDROCORTISONE ACETATE AND PRAMOXINE HYDROCHLORIDE 
hydrocortisone acetate and pramoxine hydrochloride cream
Product Information
     
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HYDROCORTISONE ACETATE (HYDROCORTISONE) HYDROCORTISONE ACETATE 25 mg  in 1 g
PRAMOXINE HYDROCHLORIDE (PRAMOXINE) PRAMOXINE HYDROCHLORIDE 10 mg  in 1 g
Inactive Ingredients
Ingredient Name Strength
WATER  
CETOSTEARYL ALCOHOL  
MINERAL OIL  
PETROLATUM  
PROPYLPARABEN  
TRIETHANOLAMINE LAURYL SULFATE  
CITRIC ACID MONOHYDRATE  
SODIUM CITRATE  
ISOPROPYL PALMITATE  
METHYL STEARIC ACID  
LANOLIN ALCOHOLS  
METHYLPARABEN  
POTASSIUM SORBATE  
SORBIC ACID  
PEG-40 STEARATE  
CERESIN  
Packaging
# Item Code Package Description
1 4 g in 1 TUBE, WITH APPLICATOR
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 02/01/2010
Part 2 of 2
PRAMOXINE HCL 
pramoxine hcl swab
Product Information
     
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
PRAMOXINE HYDROCHLORIDE (PRAMOXINE) PRAMOXINE HYDROCHLORIDE 10 mg  in 1 g
Inactive Ingredients
Ingredient Name Strength
CITRIC ACID MONOHYDRATE  
GLYCERIN  
PHENOXYETHANOL  
POTASSIUM SORBATE  
WATER  
SODIUM CITRATE  
Packaging
# Item Code Package Description
1 6 g in 1 POUCH
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 02/01/2010
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 02/01/2010
Labeler - Acella Pharmaceuticals, LLC (825380939)
Revised: 11/2012
 
Acella Pharmaceuticals, LLC



Hide
(web1)